| Dr Scott R Chaiet, MD | |
|
600 Highland Ave, Madison, WI 53792-3409 | |
| (608) 263-6190 | |
| (608) 263-6199 |
| Full Name | Dr Scott R Chaiet |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 17 Years |
| Location | 600 Highland Ave, Madison, Wisconsin |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184828170 | NPI | - | NPPES |
| 52341-20 | Other | WI | STATE LICENSE |
| 264093-1 | Other | NY | STATE LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 52341-20 (Wisconsin) | Secondary |
| 207YX0905X | Otolaryngology - Otolaryngology/facial Plastic Surgery | 52341-20 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Wi Hospitals & Clinics Authority | Madison, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Wisconsin Medical Foundation Inc | 6608785464 | 2164 |
News Archive
A national clinical trial, which opens imminently, will aim to assess the impact of a novel anti-cancer drug in the setting of donor bone marrow transplantation for myeloma.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, presented clinical data and analysis from its Phase 2a clinical trial of LX4211 for patients with type 2 diabetes mellitus at ENDO 2010 today. The results reported today included newly-obtained data showing a trend of increased total GLP-1 in both LX4211 treatment arms relative to placebo as measured in a post-trial analysis of blood samples.
Until now, it has been assumed that people with diseases like ADHD, Tourette syndrome, obsessive compulsive disorder and schizophrenia - all of whom characteristically report symptoms of "brain clutter" - may suffer from anomalies in the brain's prefrontal cortex.
Results of an analysis from the University of Cincinnati College of Medicine show that additional therapy, or adjuvant therapy, delivered after surgical removal of a rare type of gastrointestinal tumor does not increase survival rates for patients.
After a High Court case, an HIV prevention drug is soon to be available on the NHS. NHS England has issued a statement saying that pre-exposure prophylaxis (PrEP) treatment for HIV shall be available to an initial 10,000 people for a trial period of three years.
› Verified 6 days ago
| Entity Name | University Of Wisconsin Medical Foundation Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598784555 PECOS PAC ID: 6608785464 Enrollment ID: O20031111000435 |
News Archive
A national clinical trial, which opens imminently, will aim to assess the impact of a novel anti-cancer drug in the setting of donor bone marrow transplantation for myeloma.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, presented clinical data and analysis from its Phase 2a clinical trial of LX4211 for patients with type 2 diabetes mellitus at ENDO 2010 today. The results reported today included newly-obtained data showing a trend of increased total GLP-1 in both LX4211 treatment arms relative to placebo as measured in a post-trial analysis of blood samples.
Until now, it has been assumed that people with diseases like ADHD, Tourette syndrome, obsessive compulsive disorder and schizophrenia - all of whom characteristically report symptoms of "brain clutter" - may suffer from anomalies in the brain's prefrontal cortex.
Results of an analysis from the University of Cincinnati College of Medicine show that additional therapy, or adjuvant therapy, delivered after surgical removal of a rare type of gastrointestinal tumor does not increase survival rates for patients.
After a High Court case, an HIV prevention drug is soon to be available on the NHS. NHS England has issued a statement saying that pre-exposure prophylaxis (PrEP) treatment for HIV shall be available to an initial 10,000 people for a trial period of three years.
› Verified 6 days ago
| Entity Name | University Of Wisconsin System Non Payroll |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346266319 PECOS PAC ID: 9133024888 Enrollment ID: O20031204001102 |
News Archive
A national clinical trial, which opens imminently, will aim to assess the impact of a novel anti-cancer drug in the setting of donor bone marrow transplantation for myeloma.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, presented clinical data and analysis from its Phase 2a clinical trial of LX4211 for patients with type 2 diabetes mellitus at ENDO 2010 today. The results reported today included newly-obtained data showing a trend of increased total GLP-1 in both LX4211 treatment arms relative to placebo as measured in a post-trial analysis of blood samples.
Until now, it has been assumed that people with diseases like ADHD, Tourette syndrome, obsessive compulsive disorder and schizophrenia - all of whom characteristically report symptoms of "brain clutter" - may suffer from anomalies in the brain's prefrontal cortex.
Results of an analysis from the University of Cincinnati College of Medicine show that additional therapy, or adjuvant therapy, delivered after surgical removal of a rare type of gastrointestinal tumor does not increase survival rates for patients.
After a High Court case, an HIV prevention drug is soon to be available on the NHS. NHS England has issued a statement saying that pre-exposure prophylaxis (PrEP) treatment for HIV shall be available to an initial 10,000 people for a trial period of three years.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Scott R Chaiet, MD 7974 Uw Health Ct, Middleton, WI 53562-5531 Ph: () - | Dr Scott R Chaiet, MD 600 Highland Ave, Madison, WI 53792-3409 Ph: (608) 263-6190 |
News Archive
A national clinical trial, which opens imminently, will aim to assess the impact of a novel anti-cancer drug in the setting of donor bone marrow transplantation for myeloma.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, presented clinical data and analysis from its Phase 2a clinical trial of LX4211 for patients with type 2 diabetes mellitus at ENDO 2010 today. The results reported today included newly-obtained data showing a trend of increased total GLP-1 in both LX4211 treatment arms relative to placebo as measured in a post-trial analysis of blood samples.
Until now, it has been assumed that people with diseases like ADHD, Tourette syndrome, obsessive compulsive disorder and schizophrenia - all of whom characteristically report symptoms of "brain clutter" - may suffer from anomalies in the brain's prefrontal cortex.
Results of an analysis from the University of Cincinnati College of Medicine show that additional therapy, or adjuvant therapy, delivered after surgical removal of a rare type of gastrointestinal tumor does not increase survival rates for patients.
After a High Court case, an HIV prevention drug is soon to be available on the NHS. NHS England has issued a statement saying that pre-exposure prophylaxis (PrEP) treatment for HIV shall be available to an initial 10,000 people for a trial period of three years.
› Verified 6 days ago
Charles N Ford, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 600 Highland Ave, Madison, WI 53792 Phone: 608-263-6190 Fax: 608-263-6199 | |
Ruth Jennifer Davis, Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 600 Highland Ave, Madison, WI 53792 Phone: 608-263-6190 Fax: 608-263-6199 | |
Chelsea M Kruse, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: Uw Hospitals & Clinics 600 Highland Ave, Madison, WI 53792 Phone: 563-880-4962 | |
Jason S Isenberg, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1211 Fish Hatchery Rd, Madison, WI 53715 Phone: 608-252-8000 Fax: 608-283-7381 | |
Dr. Ian Joseph Koszewski, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: Uw Hospital And Clinics, 600 Highland Ave, H4/831, Madison, WI 53792 Phone: 608-263-0192 | |
Dr. Joseph Paul Roche, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 600 Highland Ave, Madison, WI 53792 Phone: 608-263-6190 Fax: 608-263-6199 | |
Dr. Paula Demetrio De Souza Franca, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 600 Highland Ave, Madison, WI 53792 Phone: 608-263-6400 |